At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
BIA 2-093 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating BIA 2-093 and Oxcarbazepine for Epilepsy. Completed, enrolled 12 participants across 1 site.
Detailed Summary
To investigate the steady-state pharmacokinetics of once-daily and twice-daily regimens of BIA 2-093 and twice-daily regimen of Oxcarbazepine (Trileptal®) in healthy subjects and to assess the tolerability of such regimens in healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesPortugal
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2003
Primary CompletionDec 2003
First PostedSep 2012
TodayJul 2026
First PostedSep 5, 2012
Enrollment StartOct 1, 2003
Primary CompletionDec 1, 2003
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.8 years ago
Interventions
BIA 2-093drug
Oxcarbazepinedrug